Multimorbidity, polypharmacy and regimen complexity: the example of people with cognitive and functional decline

• In: SYMPOSIUM: PHARMACOEPIDEMIOLOGY: BRIDGING PHARMACEUTICAL SCIENCE AND PRACTICE on Monday, 14 April 2014, 10:30-12:00
• At: PSWC, Melbourne (Australia) (2014)
• Type: Presentation
• By: BELL, Simon (Monash University, Centre for Medicine Use and Safety, Parkville, Australia)
• Abstract:

  Polypharmacy and multimorbidity are common exclusion criteria in randomised controlled trials (RCTs). RCTs may be underpowered or not designed to assess a range of adverse events considered important to older people, including impaired cognition, hospitalisation and institutionalisation. Most RCTs have a drug-specific focus without considering an..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login